Aoli Wang

3.2k citations

87 papers · 2.7k · 2 hit papers · h-index 21

Impact in

Nephrology top 5%
- Gout, Hyperuricemia, Uric Acid
Biological Psychiatry top 5%

Papers in

Genetics 26
- Chronic Lymphocytic Leukemia Research 23
Hematology 26
- Chronic Myeloid Leukemia Treatments 18
- Acute Myeloid Leukemia Research 8

Co-authors: Qingsong Liu (45 shared papers)Chao Wang (2 shared papers)Wei Jiang (2 shared papers)Xianming Deng (2 shared papers)Hongbin He (2 shared papers)Rongbin Zhou (2 shared papers)Yun Chen (1 shared paper)Jin Ye (1 shared paper)
Journals: Journal of Medicinal Chemistry (18 papers)European Journal of Medicinal Chemistry (12 papers)Oncotarget (7 papers)Signal Transduction and Targeted Therapy (5 papers)Acta Pharmacologica Sinica (5 papers)
Partner nations: China United States United Kingdom

In The Last Decade

Aoli Wang

83 papers receiving 2.6k citations

Aoli Wang's Hit Papers

align trajectories log scale

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity 2018 · 674 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2018 Nature Communications
2017 The Journal of Experimental Medicine

Peers

Countries citing papers authored by Aoli Wang

Since Specialization

Citations

This map shows the geographic impact of Aoli Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aoli Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aoli Wang more than expected).

Fields of papers citing papers by Aoli Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aoli Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aoli Wang. The network helps show where Aoli Wang may publish in the future.

Co-authors

The 25 scholars most cited alongside Aoli Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aoli Wang Line = papers co-authored together Aoli Wang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity Nature Communications ·Hongbin He, Hua Jiang, Yun Chen, Jin Ye, Aoli Wang, Chao Wang, Qingsong Liu, Gaolin Liang Hit paper breakdown →	2018	674
2	Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders The Journal of Experimental Medicine ·Hua Jiang, Hongbin He, Yun Chen, Wei Huang, Jinbo Cheng, Jin Ye, Aoli Wang, Jin‐Hui Tao Hit paper breakdown →	2017	649
3	Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma ACS Chemical Biology ·Hong Wu, Wenchao Wang, Feiyang Liu, Ellen Weisberg, Bei Tian, Yongfei Chen, Binhua Li, Aoli Wang	2014	63
4	Variation of gut microbiota caused by an imbalance diet is detrimental to bugs' survival The Science of The Total Environment ·Jing Luo, Yanxia Cheng, Libin Guo, Aoli Wang, Min Lu, Letian Xu	2021	57
5	Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC European Journal of Medicinal Chemistry ·Yongfei Chen, Jiaxin Wu, Aoli Wang, Ziping Qi, Tao-Shan Jiang, Chen Cheng, Fengming Zou, Chen Hu	2017	57
6	Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells Oncotarget ·Hong Yang Wu, Aoli Wang, Wei Zhang, Beilei Wang, Cheng Chen, Wenchao Wang, Hu Chen, Zi Ye	2015	43
7	Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor European Journal of Medicinal Chemistry ·Beilei Wang, Jiaxin Wu, Yun Juan Wu, Cheng Chen, Fengming Zou, Aoli Wang, Hong Wu, Zhenquan Hu	2018	42
8	Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation Oncotarget ·Aoli Wang, Xiao-E Yan, Hong Yang Wu, Wenchao Wang, Hu Chen, Chen Cheng, Zheng Zhao, Peng Zhao	2016	41
9	Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52 Acta Pharmacologica Sinica ·Wenliang Wang, Zongru Jiang, Chen Hu, Cheng Chen, Zhenquan Hu, Aoli Wang, Li Wang, Jing L. Liu	2020	38
10	Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML Journal of Medicinal Chemistry ·Aoli Wang, Xixiang Li, Cheng Chen, Wu Hong, Ziping Qi, Chen Hu, Kailin Yu, Jiaxin Wu	2017	36
11	Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent Acta Pharmaceutica Sinica B ·Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu	2019	31
12	Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway Acta Pharmacologica Sinica ·Cheng Chen, Chuan-dong Cheng, Hong Wu, Zuowei Wang, Li Wang, Zongru Jiang, Aoli Wang, Chen Hu	2020	30
13	Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia Journal of Medicinal Chemistry ·Xixiang Li, Aoli Wang, Kailin Yu, Ziping Qi, Cheng Chen, Wenchao Wang, Hu Chen, Wu Hong	2015	30
14	Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode Journal of Medicinal Chemistry ·Aoli Wang, Xixiang Li, Hong Wu, Fengming Zou, Xiao-E Yan, Chen Cheng, Chen Hu, Kailin Yu	2017	29
15	Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies Signal Transduction and Targeted Therapy ·Husheng Mei, Hong Wu, Jing Chun Yang, Bin Zhou, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang	2023	26
16	Discovery of N -(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia Journal of Medicinal Chemistry ·Xiaofei Liang, Beilei Wang, Cheng Chen, Aoli Wang, Hu Chen, Fengming Zou, Kailin Yu, Qingwang Liu	2018	25
17	Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML Oncotarget ·Aoli Wang, Wu Hong, Chen Cheng, Chen Hu, Ziping Qi, Wenchao Wang, Kailin Yu, Xiaochuan Liu	2016	23
18	Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences Molecular Biomedicine ·Aoli Wang, Yong Chang Sun, Qingwang Liu, Hong Wu, Juan Liu, Junling Yu, Junling Yu, Qing Qing Chen	2020	23
19	Cytotoxic clerodane furanoditerpenoids from the root of Tinospora sagittata Phytochemistry Letters ·Ningbo Qin, Aoli Wang, Dahong Li, Kai‐Bo Wang, Bin Lin, Zhan‐Lin Li, Huiming Hua	2015	22
20	Insights into the molecular recognition of the granuphilin C2A domain with PI(4,5)P2 Chemistry and Physics of Lipids ·Chanjuan Wan, Bo Wu, Zhenwei Song, Jiahai Zhang, Huiying Chu, Aoli Wang, Qingsong Liu, Yunyu Shi	2015	22

About Aoli Wang

Aoli Wang is a scholar working on Genetics, Hematology, Molecular Biology, Gastroenterology and Oncology, having authored 87 papers that have together received 2.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (23 papers), Chronic Myeloid Leukemia Treatments (18 papers), PI3K/AKT/mTOR signaling in cancer (11 papers), Acute Myeloid Leukemia Research (8 papers), Gastrointestinal Tumor Research and Treatment (6 papers), Histone Deacetylase Inhibitors Research (5 papers), Hippo pathway signaling and YAP/TAZ (5 papers) and Quinazolinone synthesis and applications (5 papers). The work is most often cited by research in Nephrology (235 citations), Biological Psychiatry (69 citations), Molecular Biology (1.8k citations), Hematology (265 citations) and Genetics (243 citations). Aoli Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Qingsong Liu, Chao Wang, Wei Jiang, Xianming Deng, Hongbin He, Rongbin Zhou, Yun Chen, Jin Ye, Hua Jiang and Gaolin Liang. Their work appears in journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Oncotarget, Signal Transduction and Targeted Therapy and Acta Pharmacologica Sinica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Aoli Wang

Impact in

Papers in i

In The Last Decade

Aoli Wang

Aoli Wang's Hit Papers

Peers

Countries citing papers authored by Aoli Wang

Fields of papers citing papers by Aoli Wang

All Works

About Aoli Wang

Explore authors with similar magnitude of impact

Papers in